OneOncology brings the most advanced cancer care options to the community—offering cutting-edge technologies that heretofore were only available at major medical centers. Formed by the coming together of three of the country’s largest community-based cancer practices—Tennessee Oncology, New York Cancer & Blood Specialists and West Cancer Center—the venture utilizes state-of-art electronic health record technology developed by Flatiron Health (acquired by Roche).
Since the launch OneOncology continues to expand now with 242 oncology providers, 134 care sites and 167,000 oncology patients seen in 2019. Since their inception, they have added Arizona Blood & Cancer Specialists.
Launched in 2018, the company was conceived with a $200 million investment from General Atlantic, a private equity firm. Tracy Bahl, a formed CVS Health executive, serves as president and CEO. Each participating practice possess an equity state in OneOncology.
Clinical Research as a Care Option
The growing trend in cancer, to bring the state-of-the-art oncology therapies to the patients, no matter where they are. This represents a core underlying OneOncology meeting.
Partnered with Flatiron, OneOncology seeks to transcend “silos” breaking down walls of data and opening up deeper analyses from real-world evidence. With OneOncology’s approach to technology, for example, clinical trial accrual can increase hence improving precision medicine options, ultimately propelling value-based care models.
OneOncology leads the way bringing advanced cancer treatments to the community. Advancements in technology that were traditionally expected only at major medical centers now is offered to every growing numbers of community members across the country.
Call to Action: Interested in learning more about OneOncology? Contact them here.